Targeting blood vessels for the treatment of non-small cell lung cancer

Current Cancer Drug Targets

Volumn 8, Issue 5, 2008, Pages 392-403

  Amir, Ethan ^a   Hughes, Sarah ^a   Blackhall, Fiona ^a   Thatcher, Nick ^a   Ostoros, Gyula ^b   Timar, Jozsef ^c   Tovari, Jozsef ^b,c   Kovacs, Gabor ^b   Dome, Balazs ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MATRIX METALLOPROTEINASE INHIBITOR; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; ZYBRESTAT;

ANOREXIA; BLEEDING; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CAPILLARY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEMOPTYSIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPONATREMIA; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEINURIA; QT PROLONGATION; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48849115091     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785133187     Document Type: Review

References (113)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin. 2005, 55, 74-108.
2. Govindan, R.; Page, N.; Morgensztern, D.; Read, W.; Tierney, R.; Vlahiotis, A.; Spitznagel, E. L.; Piccirillo, J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24, 4539-4544.
3. Pfister, D. G.; Johnson, D. H.; Azzoli, C. G.; Sause, W.; Smith, T. J.; Baker, S. Jr.; Olak, J.; Stover, D.; Strawn, J. R.; Turrisi, A. T.; Somerfield, M. R.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 2004, 22, 330-353.
4. Schiller, J. H.; Harrington, D.; Belani, C. P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
5. Delbaldo, C.; Michiels, S.; Syz, N.; Soria, J. C.; Le Chevalier, T.; Pignon, J. P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292, 470-484.
6. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
7. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
8. Fontanini, G.; Vignati, S.; Boldrini, L.; Chinè, S.; Silvestri, V.; Lucchi, M.; Mussi, A.; Angeletti, C. A.; Bevilacqua, G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. 1997, 3, 861-865.
9. Han, H.; Silverman, J. F.; Santucci, T. S.; Macherey, R. S.; d'Amato, T. A.; Tung, M. Y.; Weyant, R. J.; Landreneau, R. J. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. 2001, 8, 72-79.
10. Delmotte, P.; Martin, B.; Paesmans, M.; Berghmans, T.; Mascaux, C.; Meert, A. P.; Steels, E.; Verdebout, J. M.; Lafitte, J. J.; Sculier, J. P. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis Rev. Mal. Respir. 2002, 19, 577-84.
11. Vignaud, J. M.; Marie, B.; Klein, N.; Plénat, F.; Pech, M.; Borrelly, J.; Martinet, N.; Duprez, A.; Martinet, Y. The role of plateletderived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer. Cancer Res. 1994, 54, 5455-5463.
12. Iwasaki, A.; Kuwahara, M.; Yoshinaga, Y.; Shirakusa, T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur. J. Cardiothorac. Surg. 2004, 25, 443-448.
13. Shiraga, M.; Yano, S.; Yamamoto, A.; Ogawa, H.; Goto, H.; Miki, T.; Miki, K.; Zhang, H.; Sone, S. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res. 2002, 62, 5967-5973.
14. Ellis, L. M. Epidermal growth factor receptor in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 2004, 18, 1007-1021, viii.
15. Zhang, L.; Chen, J.; Ke, Y.; Mansel, R. E.; Jiang, W. G. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J. Surg. Oncol. 2005, 3, 68.
16. Chen, J. J.; Yao, P. L.; Yuan, A.; Hong, T. M.; Shun, C. T.; Kuo, M. L.; Lee, Y. C.; Yang, P. C. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin. Cancer Res. 2003, 9, 729-737.
17. Olivero, M.; Rizzo, M.; Madeddu, R.; Casadio, C.; Pennacchietti, S.; Nicotra, M. R.; Prat, M.; Maggi, G.; Arena, N.; Natali, P. G.; Comoglio, P. M.; Di Renzo, M. F. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer 1996, 74, 1862-1868.
18. Tanaka, F.; Ishikawa, S.; Yanagihara, K.; Miyahara, R.; Kawano, Y.; Li, M.; Otake, Y.; Wada, H. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002, 62, 7124-7129.
19. Serini, G.; Valdembri, D.; Bussolino, F. Integrins and angiogenesis: a sticky business. Exp. Cell. Res. 2006, 312, 651-658.
20. Dome, B.; Hendrix, M. J.; Paku, S.; Tovari, J.; Timar, J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am. J. Pathol. 2007, 170, 1-15.
21. Pezzella, F.; Pastorino, U.; Tagliabue, E.; Andreola, S.; Sozzi, G.; Gasparini, G.; Menard, S.; Gatter, K. C.; Harris, A. L.; Fox, S.; Buyse, M.; Pilotti, S.; Pierotti, M.; Rilke, F.: Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am. J. Pathol. 1997, 151, 1417-1423.
22. Passalidou, E.; Trivella, M.; Singh, N.; Ferguson, M.; Hu, J.; Cesario, A.; Granone, P.; Nicholson, A. G.; Goldstraw, P.; Ratcliffe, C.; Tetlow, M.; Leigh, I.; Harris, A. L.; Gatter, K. C.; Pezzella, F. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br. J. Cancer 2002, 86, 244-249.
23. Hu, J.; Bianchi, F.; Ferguson, M.; Cesario, A.; Margaritora, S.; Granone, P.; Goldstraw, P.; Tetlow, M.; Ratcliffe, C.; Nicholson, A. G.; Harris, A.; Gatter, K.; Pezzella, F. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005, 24, 1212-1219.
24. Dome, B.; Dobos, J.; Tovari, J.; Paku, S.; Kovacs, G.; Ostoros, G.; Timar, J. Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A. 2008, 73, 186-193.
25. Li, X.; Tjwa, M.; Moons, L.; Fons, P.; Noel, A.; Ny, A.; Zhou, J. M.; Lennartsson, J.; Li, H.; Luttun, A.; Ponten, A.; Devy, L.; Bouche, A.; Oh, H.; Manderveld, A; Blacher, S.; Communi, D.; Savi, P.; Bono, F.; Dewerchin, M.; Foidart, J. M.; Autiero, M.; Herbert, J. M.; Collen, D.; Heldin, C. H.; Eriksson, U.; Carmeliet, P. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J. Clin. Invest. 2005, 115, 118-127.
26. Li, B.; Sharpe, E. E.; Maupin, A. B.; Teleron, A. A.; Pyle, A. L.; Carmeliet, P.; Young, P. P. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006, 20, 1495-1497.
27. Aicher, A.; Heeschen, C.; Mildner-Rihm, C.; Urbich, C.; Ihling, C.; Technau-Ihling, K.; Zeiher, A. M.; Dimmeler, S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003, 9, 1370-1376.
28. Moore, M. A.; Hattori, K.; Heissig, B.; Shieh, J. H.; Dias, S.; Crystal, R. G.; Rafii, S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann. N.Y. Acad. Sci. 2001, 938, 36-47.
29. Llevadot, J.; Murasawa, S.; Kureish, Y.; Uchida, S.; Masuda, H.; Kawamoto, A.; Walsh, K.; Isner, J. M.; Asahara, T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 2001, 108, 399-405.
30. Strehlow, K.; Werner, N.; Berweiler, J.; Link, A.; Dirnagl, U.; Priller, J.; Laufs, K.; Ghaeni, L.; Milosevic, M.; Bohm, M.; Nickenig, G. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107, 3059-3065.
31. Seeger, F. H.; Haendeler, J.; Walter, D. H.; Rochwalsky, U.; Reinhold, J.; Urbich, C.; Rossig, L.; Corbaz, A.; Chvatchko, Y.; Zeiher, A. M.; Dimmeler, S. p38 mitogen-activated protein kinase down-regulates endothelial progenitor cells. Circulation 2005, 111, 1184-1191.
32. Verma, S.; Kuliszewski, M. A.; Li, S. H.; Szmitko, P. E.; Zucco, L.; Wang, C. H.; Badiwala, M. V.; Mickle, D. A.; Weisel, R. D.; Fedak, P. W.; Stewart, D. J.; Kutryk, M. J. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004, 109, 2058-2067.
33. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J. M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964-967.
34. Ho, J. W.; Pang, R. W.; Lau, C.; Sun, C. K.; Yu, W. C.; Fan, S. T.; Poon, R. T. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006, 44, 836-843.
35. Furstenberger, G.; von Moos, R.; Lucas, R.; Thurlimann, B.; Senn H. J.; Hamacher, J.; Boneberg, E. M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 2006, 94, 524-531.
36. Willett, C. G.; Boucher, Y.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Tong, R. T.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Kozin, S. V.; Mino, M.; Cohen, K. S.; Scadden, D. T.; Hartford, A. C.; Fischman, A. J.; Clark, J. W.; Ryan, D. P.; Zhu, A. X.; Blaszkowsky, L. S.; Chen, H. X.; Shellito, P. C.; Lauwers, G. Y.; Jain, R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
37. Zhang, H.; Vakil, V.; Braunstein, M.; Smith, E. L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J. R.; Hussain, M. M.; Klueppelberg, U.; Norin, A. J.; Akman, H. O.; Ozcelik, T.; Batuman, O. A. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105, 3286-3294.
38. Massa, M.; Rosti, V.; Ramajoli, I.; Campanelli, R.; Pecci, A.; Viarengo, G.; Meli, V.; Marchetti, M.; Hoffman, R.; Barosi, G. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J. Clin. Oncol. 2005, 23, 5688-5695.
39. Igreja, C.; Courinha, M.; Cachaco, A. S.; Pereira, T.; Cabecadas, J.; da Silva, M. G.; Dias, S. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 2007, 92, 469-477.
40. Wierzbowska, A.; Robak, T.; Krawczynska, A.; Wrzesien-Kus, A.; Pluta, A.; Cebula, B.; Smolewski, P. Circulating endothelial cells in patients with acute myeloid leukemia. Eur. J. Haematol. 2005, 75, 492-497.
41. Zheng, P. P.; Hop, W. C.; Luider, T. M.; Sillevis Smitt, P. A.; Kros, J. M. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol. 2007, 62, 40-48.
42. Dome, B.; Timar, J.; Dobos, J.; Meszaros, L.; Raso, E.; Paku, S.; Kenessey, I.; Ostoros, G.; Magyar, M.; Ladanyi, A.; Bogos, K.; Tovari, J. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer. Res. 2006, 66, 7341-7347.
43. Hilbe, W.; Dirnhofer, S.; Oberwasserlechner, F.; Schmid, T.; Gunsilius, E.; Hilbe, G.; Wöll, E.; Kähler, C. M. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 2004, 57, 965-969.
44. Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A.; Horsman, M. R.; Marme, D.; Lorusso, P. M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 2005, 11, 416-420.
45. Bonomi, P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin. Oncol. 2002, 29, 78-86.
46. Leighl, N. B.; Paz-Arez, L.; Douillard, J. L.; Peschel, C.; Arnold, A.; Depierre, A.; Santoro, A.; Betticher, D. C.; Gatzemeier, U.; Jassem, J.; Crawford, J.; Tu, D.; Bezjak, A.; Humphrey, J. S.; Voi, M.; Galbraith, S.; Hann, K.; Seymour, L.; Shepherd, F. A. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. 2005, 23, 2831-2839.
47. Fontanini, G.; Vignati, S.; Boldrini, L.; Chinè, S.; Silvestri, V.; Lucchi, M.; Mussi, A.; Angeletti, C. A.; Bevilacqua, G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. 1997, 3, 861-865.
48. Gordon, M. S.; Margolin, K.; Talpaz, M.; Sledge, G. W. Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843-850.
49. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
50. rd; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
51. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
52. http://www.gene.com/gene/news/press-releases/display.do?method= detail&id=11207
53. Petit, A. M.; Rak, J.; Hung, M. C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997, 151, 1523-1530.
54. Hirata, A.; Ogawa, S.; Kometani, T.; Kuwano, T.; Naito, S.; Kuwano, M.; Ono, M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002, 62, 2554-2560.
55. Byers, L. A.; Heymach, J. V. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin. Lung Cancer 2007, 8(Suppl. 2), S79-S85.
56. Amin, D. N.; Bielenberg, D. R.; Lifshits, E.; Heymach, J. V.; Klagsbrun, M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc. Res. 2008, Mar 18. [Epub ahead of print].
57. Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; Hart, L.; Melnyk, O.; Ramies, D.; Lin, M.; Sandler, A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 4743-4750.
58. Wedge, S. R.; Ogilvie, D. J.; Dukes, M; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S.; Curry, B.; Richmond, G. H.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
59. Santoro, M.; Melillo, R. M.; Carlomagno, F.; Fusco, A.; Vecchio, G. Molecular mechanisms of RET activation in human cancer. Ann. N.Y. Acad. Sci. 2002, 963, 116-121.
60. Tamura, T.; Minami, H.; Yamada, Y.; Yamamoto, N.; Shimoyama, T.; Murukami, H.; Horiike, A.; Fujisaka, Y.; Shinkai, T.; Tahara, M.; Kawada, K.; Ebi, H.; Sasaki, Y.; Jiang, H.; Saijo, N. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thoracic Oncol. 2006, 1, 1002-1009.
61. Heymach, J. V.; Johnson, B. E.; Prager, D.; Csada, E.; Roubec, J.; Pesek, M.; Spásová, I.; Belani, C. P.; Bodrogi, I.; Gadgeel, S.; Kennedy, S. J.; Hou, J.; Herbst, R. S. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 4270-4277.
62. Riely, G. J.; Miller, V. A. Vascular endothelial growth factor trap in non small cell lung cancer. Clin. Cancer Res. 2007, 13, s4623-s4627.
63. Wilhelm, S. M.; Carter, M.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlack, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Vosnesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
64. Gollob, J. A.; Wilhelm, S.; Carter, C.; Kelley, S. L. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 2006, 33, 392-406.
65. http://www.press.bayer.com/baynews/baynews.nsf/id/ 7F2163C8C6C18519C12573F30051050E?Open&ccm=001
66. Timar, J.; Dome, B. Antiangiogenic Drugs and Tyrosine Kinases. Anticancer Agents Med. Chem. 2008, 8(5), 462-469.
67. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101, 3597-605.
68. Benjamin, L. E.; Golijanin, D.; Itin, A.; Pode, D.; Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103, 159-165.
69. Patterson, D. M.; Rustin, G. J. Vascular damaging agents. Clin. Oncol. (R Coll Radiol). 2007, 19, 443-456.
70. Garanger, E.; Boturyn, D.; Dumy, P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem. 2007, 7, 552-558.
71. Sánchez-Elsner, T.; Botella, L. M.; Velasco, B.; Langa, C.; Bernabéu, C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 2002, 277, 43799-43808.
72. Murata, R.; Siemann, D. W.; Overgaard, J.; Horsman, M. R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 2001, 156, 503-509.
73. Siim, B. G.; Lee, A. E.; Shalal-Zwain, S.; Pruijn, F. B.; McKeage, M. J.; Wilson, W. R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 2003, 51, 43-52.
74. Siemann, D. W.; Mercer, E.; Lepler, S.; Rojiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 2002, 99, 1-6.
75. Chaplin, D. J.; Pettit, G. R.; Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19, 189-195.
76. http://clinicaltrials.gov/ct2/show/NCT00113438?term=ca4p&rank=1 (accessed December 2007)
77. www.oxigene.com/vascular/vascular.asp#ZYBRESTAT (accessed December 2007)
78. Ozawa, Y.; Sugi, N. H.; Nagasu, T.; Owa, T.; Wantanabe, T.; Koyanagi, N.; Yoshino, H.; Kitoh, K.; Yoshimatsu, K. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur. J. Cancer 2001, 37, 2275-2282.
79. Hande, K. R.; Hagey, A.; Berlin, J.; Cai, Y.; Meek, K.; Kobayashi, H.; Lockhart, A. C.; Medina, D.; Sosman, J.; Gordon, G. B.; Rothenberg, M. L. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin. Cancer Res. 2006, 12, 2834-2840.
80. Fox, E.; Maris, J. M.; Widemann, B. C.; Meek, K.; Goodwin, A.; Goodspeed, W.; Kromplewski, M.; Fouts, M. E.; Medina, D.; Cho, S. Y.; Cohn, S. L.; Krivoshik, A.; Hagey, A. E.; Adamson, P. C.; Balis, F. M. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin. Cancer Res. 2006, 12, 4882-4887.
81. Yee, K. W.; Hagey, A.; Verstovsek, S.; Cortes, J.; Garcia-Manero, G.; O'Brien, S. M.; Faderl, S.; Thomas, D.; Wierda, W.; Kornblau, S.; Ferrajoli, A.; Albitar, M.; McKeegan, E.; Grimm, D. R.; Mueller, T.; Holley-Shanks, R. R.; Sahelijo, L.; Gordon, G. B.; Kantarjian, H. M.; Giles, F. J. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2005, 11, 6615-6624.
82. http://clinicaltrials.gov/ct2/show/NCT00354562?term=ABT- 751+lung&rank=1
83. http://clinicaltrials.gov/ct2/show/NCT00297089?term=ABT- 751+lung&rank=3
84. http://clinicaltrials.gov/ct2/show/NCT00073151?term=ABT- 751+lung&rank=2
85. Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C. R.; Man, S.; Cheung, A. M.; Hicklin, D. J.; Chaplin, D.; Foster, F. S.; Benezra, R.; Kerbel, R. S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313, 1785-1787.
86. Willett, C. G.; Boucher, Y.; Duda, D. G.; di Tomaso, E.; Munn, L. L.; Tong, R. T.; Kozin, S. V.; Petit, L.; Jain, R. K.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Cohen, K. S.; Scadden, D. T.; Fischman, A. J.; Clark, J. W.; Ryan, D. P.; Zhu, A. X.; Blaszkowsky, L. S.; Shellito, P. C.; Mino-Kenudson, M.; Lauwers, G. Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 2005, 23, 8136-8139.
87. Provenzale, J. M. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am. J. Roentgenol. 2007, 188, 11-23.
88. Santimaria, M.; Moscatelli, G.; Viale, G. L.; Giovannoni, L.; Neri, G.; Viti, F.; Leprini, A.; Borsi, L.; Castellani, P.; Zardi, L.; Neri, D.; Riva, P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9, 571-579.
89. Li, Y.; Yang, Z. G.; Chen, T. W.; Chen, H. J.; Sun, J. Y.; Lu, Y. R. Peripheral lung carcinoma: Correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 2007 Dec 3; [Epub ahead of print].
90. Ma, S. H.; Xu, K.; Xiao, Z. W.; Wu, M.; Sun, Z. Y.; Wang, Z. X.; Hu, Z. G.; Dai, X.; Han, M. J.; Li, Y. G. Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression. Clin. Imaging 2007, 31, 165-177.
91. Fujimoto, K.; Abe, T.; Müller, N. L.; Terasaki, H.; Kato, S.; Sadohara, J.; Kono, R.; Edamitsu, O.; Ishitake, T.; Hayashi, A.; Rikimaru, T.; Hayabuchi, N. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology 2003, 227, 786-793.
92. Guo, J.; Higashi, K.; Ueda, Y.; Oguchi, M.; Takegami, T.; Toga, H.; Sakuma, T.; Yokota, H.; Katsuda, S.; Tonami, H.; Yamamoto, I. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J. Nucl. Med. 2006, 47, 419-425.
93. Fujita, S.; Nagamachi, S.; Nishii, R.; Wakamatsu, H.; Futami, S.; Tamura, S.; Matsuzaki, Y.; Onizuka, T.; Hatakeyama, K.; Asada, Y. Relationship between cancer cell proliferation, tumour angiogenesis and 201Tl uptake in non-small cell lung cancer. Nucl. Med. Commun. 2006, 27, 989-997.
94. Drevs, J.; Zirrgiebel, U.; Schmidt-Gersbach, C. I.; Mross, K.; Medinger, M.; Lee, L.; Pinheiro, J.; Wood, J.; Thomas, A. L.; Unger, C.; Henry, A.; Steward, W. P.; Laurent, D.; Lebwohl, D.; Dugan, M.; Marmé, D. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann. Oncol. 2005, 16, 558-565.
95. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
96. Loupakis, F.; Falcone, A.; Masi, G.; Fioravanti, A.; Kerbel, R. S.; Del Tacca, M.; Bocci, G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J. Clin. Oncol. 2007, 25, 1816-1818.
97. Sweeney, C. J.; Miller, K. D.; Sissons, S. E.; Nozaki, S.; Heilman, D. K.; Shen, J.; Sledge, G. W. Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61, 3369-3372.
98. Yokoyama, Y.; Dhanabal, M.; Griffioen, A. W.; Sukhatme, V. P.; Ramakrishnan, S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 2000, 60, 2190-2196.
99. Mauceri, H. J.; Hanna, N. N.; Beckett, M. A.; Gorski, D. H.; Staba, M. J.; Stellato, K. A.; Bigelow, K.; Heimann, R.; Gately, S.; Dhanabal, M.; Soff, G. A.; Sukhatme, V. P.; Kufe, D. W.; Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998, 394, 287-291.
100. Haines, I. E.; Miklos, G. L.; Rossi, A.; Torri, V.; Gridelli, C.; Miller, K. D.; Wang, M.; Davidson, N. E. Paclitaxel plus Bevacizumab for Metastatic Breast Cancer. N. Engl. J. Med. 2008, 358, 1637-1638.
101. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
102. Baluk, P.; Hashizume, H.; McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005, 15, 102-111.
103. Masood, R.; Cai, J.; Zheng, T.; Smith, D. L.; Hinton, D. R.; Gill, P. S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98, 1904-1913.
104. Decaussin, M.; Sartelet, H.; Robert, C.; Moro, D.; Claraz, C.; Brambilla, C.; Brambilla, E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol. 1999, 188, 369-377.
105. Seto, T.; Higashiyama, M.; Funai, H.; Imamura, F.; Uematsu, K.; Seki, N.; Eguchi, K.; Yamanaka, T.; Ichinose, Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006, 53, 91-96.
106. Browder, T.; Butterfield, C. E.; Kräling, B. M.; Shi, B.; Marshall, B.; O'Reilly, M. S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60, 1878-1886.
107. Miller, K. D.; Sweeney, C. J.; Sledge, G. W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001, 19, 1195-206.
108. Pircher, A.; Kähler, C. M.; Skvortsov, S.; Dlaska, M.; Kawaguchi, G.; Schmid, T.; Gunsilius, E.; Hilbe, W. Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol. Rep. 2008, 19, 345-352.
109. Hudis, C. A. Clinical implications of antiangiogenic therapies. Oncology (Williston Park). 2005, 19(4 Suppl. 3), 26-31.
110. Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 60-65.
111. Jain, R. K.; Duda, D. G.; Clark, J. W.; Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3, 24-40.
112. Duda, D. G.; Jain, R. K.; Willett, C. G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 2007, 25, 4033-4042.
113. Relf, M.; LeJeune, S.; Scott, P. A.; Fox, S.; Smith, K.; Leek, R.; Moghaddam, A.; Whitehouse, R.; Bicknell, R.; Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57, 963-969.